Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose escalation of allogeneic adipose-derived stroma/stem cells for the treatment of Crohn’s fistula
2024-511821-75-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of allogeneic adipose-derived stromal/stem cells in Crohn's disease, sponsored by Centre hospitalier universitaire de Toulouse. Planned start Sep 2024; status: authorised.
02
Drugs
allogeneic adipose-derived stromal/stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-511821-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511821-75-00.